Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
Clinical trial NCT03625323 · COMPLETED
Trial details
- NCT number
- NCT03625323
- Sponsor
- Immutep S.A.S.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-21
- Primary completion
- 2022-06-02
- Enrollment
- 187
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.